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Abstract
The altered expression of cell adhesion molecules (CAMs) correlates with the malignant 
progression of many epithelial tumors. MUC18/CD146/A32/MelCAM/S-endo 1, a CAM 
in the immunoglobulin gene superfamily, is an integral membrane glycoprotein. MUC18 
is not a mucin, resulting from its misleading nomenclature by the original discoverer. We 
re-named it as METCAM (metastasis-regulating CAM), based on its very interesting bio-
logical roles in tumor formation and metastasis of many epithelial tumors. Initial findings 
show that METCAM/MUC18 expression has a positive effect (as a tumor and metastasis 
promoter) on the progression of breast cancer, most melanoma cell lines, nasopharyngeal 
carcinoma (NPC) type II, and prostate cancer. Later research results show that METCAM/
MUC18 expression has a negative effect (as a tumor suppressor and metastasis suppressor) 
on the progression of ovarian cancer, one mouse melanoma cell line, and nasopharyngeal 
carcinoma type I, and perhaps hemangioma. Since the above dual function of METCAM/
MUC18 occurs only in different cell lines from the same cancer type or in those from dif-
ferent cancer types, we suggest that the different effect of METCAM/MUC18 on tumor 
formation and metastasis of different cancer cell line may be due to different intrinsic prop-
erties (co-factors) in each cancer cell line that modify the biological functions of METCAM/
MUC18 in the intrinsic properties of tumor cells and their interactions with the tumor 
microenvironment. This chapter will review the published work and present some possi-
ble mechanisms for the METCAM/MUC18-mediated cancer progression for future studies.
Keywords: METCAM/MUC18, breast cancer, melanoma, nasopharyngeal carcinoma, 
ovarian cancer, prostate cancer, tumors
1. Introduction
Cancer progression is very complex because many genes are directly or indirectly involved in 
the process. The accumulation of the multiple intrinsic changes leading to aberrant alterations 
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of gene expression can contribute to tumorigenesis and its progression to the malignant phe-
notype. This is because the genome of malignant tumor cells has greater instability than non-
malignant tumor cells and renders malignant tumor cells more prone to acquiring multiple 
mutations [1]. Tumorigenesis involves expression of many oncogenes and tumor suppressor 
genes [2, 3], which will not be elaborated here. Likewise, metastasis also involves many metas-
tasis enhancer genes and metastasis suppressor genes [2, 3] ever since the successful conver-
sion of a non-metastatic Ha-ras-transformed NIH 3 T3 fibroblast cells to metastatic tumor cells 
by transfecting the cells with the DNA fragments isolated from a human metastatic tumor [4]. 
This also suggests that many alternative pathways are possible for metastasis, similar to mul-
tiple alternative pathways leading to tumorigenesis [2, 3]. This includes the genes encoding 
cell adhesion molecules (CAMs), such as E-cadherin [5], integrins α2β1 [6] and αVβ3 [7], CD44 
[8], EPCAM [9, 10], ALCAM [11], and METCAM/MUC18 [12, 13]. The list of these genes has 
been rapidly lengthened because of the advent of modern state-of-the-art technologies, such 
as SAGE analysis [14, 15], DNA chip microarray analysis [16–19], and proteomics [20–22]. 
Some of these genes may be commonly used by metastatic tumors derived from different 
tissues, if these genes render tumor cells with a metastatic advantage over other tumor cells, 
regardless of their origins. Some oncogenes or tumor suppressor genes may also play direct 
or indirect roles in tumor metastasis, if they directly or indirectly alter cytoskeleton structure, 
cellular motility, invasiveness, and render them having growth advantages in target organs.
Tumor metastases fortunately are a rare event due to metastatic inefficiency. It was originally 
thought that only a very small population of the metastatic cells could reach and establish 
the growth in the distant target organs after they successfully intravasate or extravasate the 
vasculatures or lymphatics, and then survive the assaults in the circulatory system, which 
includes the attacks from the immune system and the destructive hydrodynamic shearing [23]. 
However, recent results of observing the process with in vivo video microscopy appear to sup-
port the notion that metastatic inefficiency is more likely due to that only a small percentage 
of tumor cells are able to dock and establish secondary growths in distant organs after sur-
vival from the attacks from the immune system and the assault from the mechanical shearing, 
since both highly metastatic cells and non-metastatic cells have similar migratory and invasive 
abilities to intravasate or extravasate the circulatory systems [24]. The successful establish-
ment of secondary growth by metastatic cells may result from a complex interaction of tumor 
cells with the extracellular matrix in the favorable microenvironment of the target organs. 
This interaction may also be due to the altered expressions of many cell adhesion molecules 
(CAMs) in metastatic cells that alter their ability to interact with the extracellular matrix.
CAMs govern the social behaviors of the cells. The altered expression of CAMs affects cell-cell 
interactions and cell-extracellular matrix interactions, which results in changing the cellular 
motility and invasiveness [25]. Altered expression of CAMs also can affect survival and growth 
of tumor cells and alter angiogenesis [26]. As such, CAMs may promote or suppress the meta-
static potential of tumor cells [26]. The metastatic potential of a tumor cell could be the conse-
quence of a complex participation of many over- or under-expressed CAMs, as documented in 
many carcinomas [27]. For example, integrins αV, α4, and β3, I-CAM, METCAM/MUC18, and 
HLA-DR are over-expressed, whereas E-cadherin, α-catenin, and VCAM are under-expressed 
in metastatic melanomas [28]. On the other hand, the metastatic potential of a tumor cell could 
be due to the altered expression of a single CAM. For example, over-expression of integrin 
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α2β1 decreases the metastasis of breast carcinoma cells [6], whereas over-expression of integ-
rin αVβ3 increases the metastatic potential of human prostate carcinoma cells [7].
Effects of altered expression of I-CAM, V-CAM, some integrins (αV, α4, and ß3), L1CAM, 
METCAM/MUC18 [28], and E-cadherin [29] on the metastasis of melanoma have been dem-
onstrated. Studies of the altered expression of CAMs on the metastasis of prostate cancers are 
E-cadherin [5], CD44 [8, 30], CEA-CAM [31, 32], and some integrins [7, 33, 34]. Increased expres-
sion of E-cadherin [35] and the standard form of CD44 [8] suppresses metastasis of prostate car-
cinoma. On the contrary, increased expression of a splicing variant form of CD44, CD44v7-v10, 
correlates with the progression of prostate carcinoma and enhances in vitro invasiveness of human 
prostate cancer cell lines [30]. Increased expression of CEA-CAM1 suppresses tumorigenesis [32]; 
however, the effect on metastasis has not been tested. The effect of a single integrin mostly is not 
obvious except αVβ3, α6β1, and α3β1 integrins in prostate cancer, perhaps many members of the 
integrin family are functionally compensatory to each other [33–36]. Aberrant expression of CAMs 
has been associated with nasopharyngeal carcinoma (NPC). For examples, up-regulation of ICAM 
[37] and down-regulation of E-cadherin [38, 39] and connexin 43 [40] correlate with the progres-
sion of NPC; however, the expression of CD44 does not [38]. Aberrant expression of various CAMs 
associated with the malignant progression of ovarian cancer are mucins [41], integrins [42], CD44 
[43], L1CAM [44], E-cadherin [45], claudin-3 [46], EpCAM [9, 10], and METCAM/MUC18 [47, 48].
For the past two decades, we have focused our research on the role of METCAM/MUC18 in 
the progression of several epithelial tumors: first, we tried to correlate the expression level of 
METCAM/MUC18, which was determined by using the methods of immunohistochemistry 
and/or RT-PCR, with the pathological state of the tumor tissues and from the results to propose 
a hypothesis to predict the possible positive or negative role played by METCAM/MUC18 in the 
progression of each cancer. Then we tested the hypothesis by investigating effects of METCAM/
MUC18 over-expression or under-expression on in vitro cellular behaviors and tumorigenesis and 
on in vivo tumorigenesis in athymic nude mice, or if possible, in syngeneic mice. We studied the 
effect of the expression of METCAM/MUC18 on the progression of melanoma cell lines [49, 50] 
and prostate cancer cell lines [51–55], and then extended our research to breast cancer cell 
lines [56–58], ovarian cancer cell lines [48, 59, 60], and nasopharyngeal carcinoma cell lines [61]. 
Possible mechanisms played by METCAM/MUC18 were preliminarily determined by analyz-
ing the expression levels of several downstream effectors in the tumor tissues excised from these 
mice. In this chapter, I will summarize the findings of the above research activities and review 
the dual role of METCAM/MUC18 in the progression of breast cancer, melanoma, nasopharyn-
geal carcinoma, ovarian cancer, and prostate cancer [48–62]. I will also propose some possible 
mechanisms of METCAM/MUC18-mediated tumorigenesis and metastasis for future studies.
2. METCAM/MUC18
Human METCAM/MUC18 (huMETCAM/MUC18), a CAM in the immunoglobulin gene 
superfamily, is an integral membrane glycoprotein [63]. The name “MUC18”, which was 
originally coined by Judy Johnson [63], has often been mistaken as a new member in the 
mucin family. Other names, such as CD146, A32, and S-endo 1, were not used because they 
did not reflect its biological functions [63–68]. The names MCAM and MELCAM with an 
Dual Role of METCAM/MUC18 Expression in the Progression of Cancer Cells
http://dx.doi.org/10.5772/intechopen.72742
259
over-emphasis on its role in melanoma [28] are discarded because MUC18 is involved in the 
metastasis of many cancers besides melanoma ([69] and this review). To eliminate confusion 
and to reflect its biochemical properties and key role in the progression of epithelial tumors, 
we have created a new name for MUC18: METCAM (metastasis CAM), an immunoglobulin-
like CAM that regulates metastasis [69]. MUC18 is included in our nomenclature to com-
memorate its original discovery [63].
Judy Johnson’s group was the first group to clone and characterize the sequence of a huMET-
CAM/MUC18 cDNA from human melanoma [63]. Later my group cloned the huMETCAM/
MUC18 cDNA from several human melanoma cell lines and human prostate cancer cell lines 
[70]. The DNA sequences of our huMETCAM/MUC18 cDNA clones from three human mela-
noma cell lines, three human prostate cancer cell lines, and several human nasopharyngeal tis-
sues are similar; therefore, we conclude that our huMETCAM/MUC18 cDNA gene is the major 
common form in comparison to that of Judy Johnson. The amino acid sequences deduced from 
the DNA sequence of our huMETCAM/MUC18 cDNA differ from that of Johnson’s group 
in seven amino acids [63, 70]. Regardless of minor differences in amino acid sequences, all 
huMETCAM/MUC18 cDNAs encode 646 amino acids that include a N-terminal extracellular 
domain of 558 amino acids, of which at the N-terminus it has 28 amino acids characteristic of 
a signal peptide sequence, a transmembrane domain of 24 amino acids (amino acid #559–583), 
and an intracellular cytoplasmic domain of 64 amino acids at the C-terminus (Figure 1). The 
molecular weight of the un-glycosylated form of huMETCAM/MUC18 protein is estimated to 
be about 72 kDa [63, 69, 70]. Since huMETCAM/MUC18 has eight putative N-glycosylation 
sites (Asn-X-Ser/Thr), it is often heavily glycosylated and sialylated resulting with an apparent 
molecular weight between 113,000 and 150,000, dependent upon the tissue origin. The extra-
cellular domain of the protein contains five immunoglobulin-like domains (V-V-C2-C2-C2) 
[63, 70] and an X domain [69, 70]. The cytoplasmic domain contains peptide sequences that are 
potentially be phosphorylated by protein kinase A (PKA), protein kinase C (PKC), and casein 
kinase 2 (CK 2) [63, 64, 69, 70]. My lab has also cloned the mouse METCAM/MUC18 (moMET-
CAM/MUC18) cDNA, which contains 648 amino acids with 76.2% identity with huMETCAM/
MUC18 [71]. The structure of the huMETCAM/MUC18 protein is illustrated in Figure 1.
Similar to other CAMs, the functions of huMETCAM/MUC18 has been studied in relation to 
cell-cell and cell-extracellular matrix interactions, which trigger a cascade of signals that affect 
cytoskeleton structure and cellular motility and invasiveness. Figure 1 shows the six conserved 
Figure 1. The protein structure of human METCAM/MUC18.
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 N-glycosylation sites, which are located in the V1, the region between the C2′ and the C2″, the 
C2″, and the X domains in the extracellular domain, and five potential phosphorylation sites 
in the intracellular cytoplasmic tail. From the protein structure, we predicted that METCAM/
MUC18 may have additional functions, which may include synergistic interactions with 
growth factor receptors (as a co-receptor) to modulate cell functions and to trigger on intra-
cellular signaling pathways, activation of matrix metalloproteinases (MMPs), serving as a 
co-activator for other cell functions, and serving as a co-transporter for extracellular small 
molecules (for example, calcium ion influx) [69], as summarized in Figure 2.
HuMETCAM/MUC18 is expressed in several normal tissues/cells, such as endothelial cells, 
hair follicular cells, smooth muscle cells, normal breast epithelial cells, basal cells in bronchial 
epithelium, the cerebellum, intermediate trophoblasts, some activated T cells [66], ovarian 
epithelial cells [48], and normal nasopharynx epithelial cells [61]. In addition, huMETCAM/
MUC18 is expressed in several cancers, such as melanoma, gestational trophoblastic tumors, 
leiomyosarcoma, angiosarcoma, hemangioma, Kaposi’s sarcoma, schwannoma, some lung 
squamous and small cell carcinomas, some breast cancer, and some neuroblastoma [66]. For 
the past two decades, we have also found that huMETCAM/MUC18 is also expressed in pros-
tate cancer [72], ovarian cancer [48], and nasopharyngeal carcinoma [61].
Figure 2. A proposed model for the outside-in and inside-out signaling of METCAM/MUC18 and its possible crosstalk 
with signal transduction pathways.
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3. Role of METCM/MUC18 in the tumorigenesis and metastasis of 
different human cancers
3.1. METCAM/MUC18 plays a positive role in the progression of breast cancer
METCAM/MUC18 was suggested by two groups to play a tumor suppressor role [73, 74], but by 
the two other groups as a tumor promoter in the progression of human breast cancer [75, 76]. To 
resolve the controversial role of METCAM/MUC18 in the progression of human breast cancer, 
we set out independent studies to investigate the actual role played by METCAM/MUC18 in the 
progression of human breast cancer. We found that enforced expression of METCAM/MUC18 in 
both MCF-7 and SK-BR-3 cell lines increased their in vitro motility, invasiveness, and colony 
formation in soft agar (in vitro tumorigenesis). Furthermore, enforced expression of METCAM/
MUC18 in both cell lines increased tumor-take and tumorigenesis in athymic nude mice [56–58].
Moreover, anti-METCAM/MUC18 antibody decreased the motility and invasiveness of the two 
basal-like cell lines, MDA-MB-231 and MDA-MB-468 [57]. Enforced expression of METCAM/
MUC18 increases the metastasis of both basal-like cell lines in athymic nude mice [77]. Taken 
together, METCAM/MUC18 plays a positive role in the progression of four human breast 
cancer cell lines. Therefore, METCAM/MUC18 is a novel oncogene for mammary carcinoma 
cells and may be useful as a therapeutic target for the treatment of breast cancer. From further 
preliminary mechanical studies we suggest that METCAM/MUC18 promotes the progression 
of human breast cancer cells by increasing proliferation, angiogenesis, switching to aerobic 
glycolysis, and epithelial-to-mesenchymal transition (EMT) [56–58], thus its downstream sig-
naling molecules may also be used as therapeutic targets for the treatment of breast cancer.
3.2. METCAM/MUC18 plays a dual role in the progression of melanoma
HuMETCAM/MUC18 was highly expressed on the cellular surface of most malignant human 
melanomas and has been suggested to play a positive role in the progression of human mela-
noma [63, 64]. Three groups demonstrate that the stably ectopic expression of the huMETCAM/
MUC18 cDNA gene in three non-metastatic human cutaneous melanoma cell lines increases 
the metastatic ability of these cell lines in immune-deficient mouse models [12, 67]. Our group 
focused our studies on mouse melanomas, we show that stable, ectopic expression of moMET-
CAM/MUC18 in two low-metastatic mouse melanoma cell lines, K1735-3 and K1735-10, 
increases their metastatic abilities in immune-competent syngeneic mice [49]. METCAM/
MUC18 enables melanoma cells to establish pulmonary metastasis only when the cells are injected 
into the tail vein (experimental metastasis) [12, 13, 49, 50], thus bypassing the initial stages of 
metastasis. In contrast, no metastasis was found when METCAM/MUC18-expressing mela-
noma cells were injected subcutaneously (spontaneous metastasis) either in immune-deficient 
mouse models [12, 67] or in immune-competent syngeneic mouse models [13, 49]. We concluded 
that moMETCAM/MUC18 may promote melanoma metastasis only in the later stages of metasta-
sis. This result is consistent with the observation of one of the three original groups that huMET-
CAM/MUC18 does not initiate the conversion (transformation) of melanocytes into melanoma [78].
In contrast to the role of moMETCAM/MUC18 in promoting metastasis in the two mouse 
melanoma cell lines K1735 clone 3 and clone 10, surprisingly we found that over-expression of 
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moMETCAM/MUC18 in one mouse melanoma cell line K1735 clone 9 decreased subcutaneous 
tumorigenesis and decreased pulmonary lung nodule formation when cells were injected into 
the tail vein in an isogenic mouse model [50]. Thus MCAM/MUC18 acts as a tumor and metas-
tasis suppressor for the K1735-9 subline, different from its role in other K1735 sublines, K1735-3 
and K1735-10. We suggest that ectopic expression of MCAM/MUC18 in different sublines may 
interact with different intrinsic co-factors/ligands, which may contribute to these intrinsic proper-
ties, such as adhesion-associated signaling cascades and cytoskeleton rearrangement, leading to 
different epithelial-to-mesenchymal transition of these cells and hence the intrinsic tumorigenic 
and metastatic potential of these cells. Different intrinsic co-factors in different K1735 sublines, 
which may modulate the functions of MCAM/MUC18 in the cells, leading to interact differently 
with the tumor microenvironment, may render sublines manifest differently in tumorigenic-
ity and metastasis in vivo. Moreover, interactions of METCAM/MUC18 with these co-factors/
ligands may render different sublines/cell lines being regulated by other physiological factors 
in vivo, which may enhance or inhibit in vivo growth of the tumor cells by altering metabolic 
switch, by altering apoptosis, or by up-regulating or down-regulating angiogenesis, as well as by 
boosting up or suppressing immune system in the tumor microenvironment and in the lung [50].
These syngeneic mouse systems are more useful models than the immune-deficient mouse sys-
tems for better understanding mechanisms of the complex role played by MCAM/MUC18 in 
the progression of melanoma cells. Furthermore, since these syngeneic mouse models more 
closely mimic the clinical melanoma cases in comparison to xenograft models, the knowledge 
gained from using these systems may also be useful for designing efficacious clinical thera-
pies. Therefore, when therapeutic means are developed, we should keep in mind the dual 
role played by MCAM/MUC18. We should also be aware of the response of immunotherapy 
by using anti-METCAM/MUC18 monoclonal antibodies [79] and therapy by using MCAM/
MUC18-specifc siRNAs [80] may be different in different patients.
3.3. METCAM/MUC18 plays a dual role in the progression of nasopharyngeal 
carcinoma
Nasopharyngeal carcinoma (NPC) is a malignant head and neck cancer; 90% of that develops 
in the non-lymphomatous, squamous epithelial lining of posterior nasopharynx [81]. NPC is 
heterogeneous: it manifests one of the three subtypes (or three patterns): keratinizing squa-
mous cell carcinomas (WHO type I), non-keratinizing squamous cell carcinomas (WHO type 
II), and undifferentiated carcinomas (WHO type III) [61, 81]. Epidemiological studies suggest 
that three major etiological factors, such as genetic susceptibility, environmental factors, and 
infection with Epstein Barr virus (EBV), contribute to the extraordinary incidence in endemic 
areas [61]. However, how these major etiological factors contribute to the initiation and devel-
opment and final progression is not known. Nevertheless, these etiological factors may induce 
aberrant expression of cell adhesion molecules (CAMs) in NPC and leading to tumorigenesis 
and malignant progression. Aberrant expression of CAMs has been associated with the pro-
gression of NPC [37–40]. However, the possible aberrant expression of METCAM/MUC18 in 
nasopharyngeal carcinoma has not been studied.
We initiated the study of the possible roles of METCAM/MUC18 in the malignant progression of 
NPC by using immunohistochemistry to determine the expression of the protein in the tissues of 
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normal nasopharynx and NPC and two established NPC cell lines [61]. We found that METCAM/
MUC18 was expressed in all of the normal nasopharynx, but weakly expressed in only 27% 
of the NPC tissues, suggesting that METCAM/MUC18 may function as a tumor suppressor in 
the development of NPC during the progression of the disease [61]. To test the hypothesis, we 
investigated the effect of METCAM/MUC18 over-expression on in vitro cellular behavior and in 
vivo tumorigenesis of two NPC cell lines in athymic nude mice. Indeed, METCAM/MUC18 over-
expression suppressed the tumor growth of NPC-TW01 cells, which were established from type 
I NPC [81], as shown in [82, 83]. We suggested that METCAM/MUC18 plays a tumor suppressor 
role in the type I NPC [82, 83]. On the contrary, over-expression promoted the tumor growth of 
NPC-TW04 cells, which were established from type II NPC [81], as shown in [82, 84]. We suggest 
that METCAM/MUC18 plays a tumor promoter role in the type II NPC [82, 84].
We suggest that the dual role played by METCAM/MUC18 in the progression of two different 
types of NPC’s may be modulated by different intrinsic factors and also in different stromal 
microenvironment. These two NPC cell lines may serve as models for understanding the con-
tribution of three etiological factors to trigger the malignant progression of NPC and for trans-
lational applications. Radiotherapy has been used for the treatment of NPC; however, NPC has 
been notoriously resistant to radiotherapy. Thus, we sought the possibility of altering the radio-
sensitivity of NPC by ectopically increased expression of METCAM/MUC18 in NPC cell lines. 
Our preliminary studies show that radio-sensitivity of the tumors induced from both cell lines in 
athymic nude mice was increased by increased expression of METCAM/MUC18. Thus, ectopi-
cally increased expression of this protein may be used for clinical treatment [data not shown].
3.4. METCAM/MUC18 plays a negative role in the progression of ovarian cancer
METCAM/MUC18 expression has been recently to correlate with the progression of ovarian 
cancer [47, 48], and perhaps affect the in vitro behaviors of ovarian cancer cells [85]; however, the 
role of METCAM/MUC18 in the progression of epithelial ovarian cancer has not been directly 
studied in animal models. For this purpose, we initiated the studies by directly testing the 
effect of over-expression of METCAM/MUC18 on the ability of SK-OV-3 cells in in vitro motil-
ity and invasiveness, and in vivo tumor formation in nude mice after subcutaneous (SC) injec-
tion and in vivo progression in nude mice after intraperitoneal (IP) injection. Over-expression 
of METCAM/MUC18 inhibited in vitro motility and invasiveness [59] and suppressed in vivo 
tumorigenesis and malignant progression of the human ovarian cancer cell line SK-OV-3 [59]. 
Similar results were shown in another human ovarian cancer cell line, BG-1 (data not shown).
Taken together, we provided in vitro and in vivo evidence to support the notion that METCAM/
MUC18 plays a suppressing role in tumorigenesis and malignant progression of two human 
ovarian cancer cell lines [59, 60]. We strongly suggested that METCAM/MUC18 is a novel 
tumor and metastasis suppressor for the progression of human ovarian cancer cells.
3.5. METCAM/MUC18 plays a positive role in the progression of prostate cancer
Over-expression of METCAM/MUC18 is not limited to melanoma as previously thought and 
also later research carried out by one of the original three groups proved that MelCAM/MCAM/
MUC18 did not play an important role in converting normal melanocyte into melanoma [78]. 
With this in mind, we have initiated the study of trying to correlate the huMETCAM/MUC18 
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expression with prostate cancer at different pathological stages. Molecular biological and 
immunological methods were used to study the expression of huMETCAM/MUC18 in two 
prostate cancer cell lines (DU145 and PC-3) and in human tissues of normal prostates, BPH, 
PIN, and prostate cancer, and immunohistochemistry was used for its expression in tissue sec-
tions of paraffin-embedded human prostate cancer [70, 72]. From the results, we suggested a 
possibility that huMETCAM/MUC18 may be used as a novel early diagnostic marker for the 
metastatic potential of human prostate cancer. These notions are further strengthened by the 
results of our studies in a transgenic mouse model, transgenic adenocarcinoma mouse prostate 
(TRAMP) [52]. Furthermore, we have suggested a hypothesis that huMETCAM/MUC18 very 
likely plays an important role in tumorigenesis and metastasis of human prostate cancer cells 
[72]. Then we carried out systematic studies of huMETCAM/MUC18-mediated prostate can-
cer metastasis in animal models to test the above hypothesis. We have tested the effect of ecto-
pic expression of huMETCAM/MUC18 in human prostate LNCaP cells on their ability to form 
tumor in the non-orthotopic subcutaneous sites [53] and in the orthotopic prostate glands and 
to initiate metastasis in nude mice [51]. In contrast to melanoma cells, we have obtained evi-
dence to prove that huMETCAM/MUC18 is a key determinant in initiating the metastasis of 
prostate cancer [51]. The detailed evidence is briefly described as follows:
3.5.1. Over-expression of huMETCAM/MUC18 correlates with the development and 
malignant progression of human prostate cancer
Two groups initiated the studies by testing possible huMETCAM/MUC18 expression in pros-
tate cancer cell lines and prostate cancer tissues; however, they were unable to obtain positive 
results because the monoclonal antibodies used were incapable of recognizing the huMET-
CAM/MUC18 epitopes in prostate cancer cell lines and tissues [65, 86]. But we were able to 
use our chicken polyclonal antibodies for Western blot analysis and immunohistochemistry to 
detect the expression of huMETCAM/MUC18 antigens in prostate cancer cell lines and human 
prostate cancer tissues. We confirmed these results by using the RT-PCR analysis to show the 
presence of huMETCAM/MUC18 mRNA [70, 72]. We found that huMETCAM/MUC18 was 
neither expressed in most (90%) of the normal epithelial cells in the prostatic ducts/acini nor 
in any (100%) of these cells in BPH, but it was detectable in the majority (greater than 80%) of 
the neoplastic prostate epithelial cells (high-grade PIN), high-grade prostate adenocarcinomas, 
and metastatic lesions. HuMETCAM/MUC18 was expressed in two metastatic human prostate 
cancer cell lines, DU145 and PC-3, and one bladder cancer cell line, Tsu-Pr1, but not in one 
non-metastatic prostate cancer cell line, LNCaP [70, 72]. Thus, we conclude that huMETCAM/
MUC18 is not expressed in normal and benign hyperplastic human prostate tissues, but its 
expression increases during prostate cancer initiation (high-grade PIN), progression to carci-
noma, and in metastatic cell lines and metastatic lesions. Taken together, over-expression of 
METCAM/MUC18 correlates with the initiation of malignant progression of human prostate 
cancer [70, 72], suggesting that huMETCAM/MUC18 may be a useful marker for monitoring 
the metastatic potential of prostate cancer cells [70, 72]. Furthermore, the extent of in vitro motil-
ity and invasiveness is directly proportional to the extent of huMETCAM/MUC18 expression in 
four human cancer cell lines [70]. Our anti-huMETCAM/MUC18 antibody was able to signifi-
cantly block the in vitro motility and invasiveness of various human prostate cancer cell lines 
[70]. Therefore, we propose the hypothesis that huMETCAM/MUC18 may directly mediate the 
increased epithelial-to-mesenchymal transition and initiate the progression of prostate cancers.
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3.5.2. Correlation of over-expression of mouse METCAM/MUC18 with the malignant 
progression of prostate cancer in a transgenic mouse model (TRAMP)
If the above hypothesis is correct, we should be able to correlate moMETCAM/MUC18 expres-
sion with the development and progression of prostate cancer in a transgenic mouse model. To 
test this possibility, we have used the autochthonous TRAMP (transgenic adenocarcinoma mouse 
prostate) model for the experiment by collaborating with Dr Norman Greenberg’s group. The 
TRAMP model established by Dr Norman Greenberg [87] is one of two transgenic mouse mod-
els that have been established for studying the tumorigenesis and metastasis of prostate cancer 
[87, 88]. This model was created by transfecting the germ line of the C57BL/6 inbred strain of mice 
with fusion gene of the rat probasin (PB) gene promoter and the SV40 T antigen (Tag) gene. The 
expression of the PB-Tag transgene is regulated by androgens and only localized to the prostatic 
epithelial cells in the dorsolateral and ventral lobes. When the mice reach an age of 12–20 weeks, 
TRAMP mice histologically show mild to severe hyperplasia with cribriform structures. By an 
age of 26 weeks, severe hyperplasia and adenocarcinoma is manifested. By an age of 26–33 weeks, 
all TRAMP males show primary tumors and metastasis in the lymph nodes and lungs and less 
frequently in the bones, kidney, and adrenal glands. In this transgenic model, the epithelial origin 
of the tumors and metastatic deposits has been successfully shown [87] in prostates.
MoMETCAM/MUC18 expression was determined by Western blot analysis and/or immuno-
histochemistry by using our chicken anti-moMETCAM/MUC18 antibodies [71] during the pro-
gression of mouse prostate adenocarcinoma in this transgenic mouse model. When these mice 
reached 12–20 weeks of age, they began to show PIN in the prostate glands. When they reached 
178–181 days of age (25.7–25.9 weeks), they had primary tumors in the prostate glands and the 
expression of moMETCAM/MUC18 mRNA and protein was detectable. Tumors continued to 
grow beyond an age of 32.4 weeks, when some mice were found dead. Interestingly, metas-
tasis was found even when tumors were small (less than 0.5 g) and the level of moMETCAM/
MUC18 expression was much lower. MoMETCAM/MUC18 was not detectable in the pros-
tates of the control group (presumably having the normal organ). The tumor metastasizes to 
peri-aortic lymph nodes in all the mice that had primary tumors. Metastatic lesions were also 
observed in seminal vesicles, abdomen cavity, livers, and lungs in some mice. The expression 
of MoMETCAM/MUC18 was detectable in all PINs, prostate adenocarcinomas, and metastatic 
lesions. We concluded that the moMETCAM/MUC18 expression was increased during the pro-
gression of the mouse prostate cancer in this transgenic mouse model [52]. Bone metastasis has 
been observed, though we have not analyzed the bone samples of these transgenic mice [89].
3.5.3. Over-expression of huMETCAM/MUC18 increases the tumor-take and metastasis of 
human prostate cancer cells
To test the hypothesis that huMETCAM/MUC18 may increase the metastatic potential of human 
prostate cancer cells, we successfully obtained G418-resistant clones that express a high level 
of huMETCAM/MUC18 after transfecting the huMETCAM/MUC18 cDNA gene into a human 
prostate cancer LNCaP cell line that did not previously express huMETCAM/MUC18 and had a 
minimal ability to metastasize. We then injected these clones orthotopically into one of the dor-
solateral lobes of the prostate. We found that ectopically enforced huMETCAM/MUC18 expres-
sion increases the tumor-take and initiates the metastasis of LNCaP cells to various organs, such 
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as the seminal vesicles, the ureter, the kidney, and the peri-aortic lymph nodes, in athymic nude 
mice [51]. Since metastatic lesions were only observed in the mice with tumors, we also con-
cluded that metastasis is closely associated with the tumorigenesis, as suggested by Weiss [23], 
but tumor formation without the expression of huMETCAM/MUC18 did not lead to metastasis.
Alternatively, we have also established a xenograft mouse model to further study how the 
expression of huMETCAM/MUC18 mediates tumorigenesis of LNCaP cells. We subcutane-
ously injected the huMETCAM/MUC18-expressing LNCaP cells together with Matrigel and 
observed the appearance of tumors at different times in a nude mouse model [53]. We found 
that ectopic (or enforced) expression of huMETCAM/MUC18 increased the early on-set of 
tumorigenesis of LNCaP cells in this mouse model [53]. Ectopic (or enforced) expression 
of huMETCAM/MUC18 increases the tumor formation of LNCaP cells [53]. We concluded 
that the enforced expression of huMETCAM/MUC18 in human prostate cancer LNCaP cells 
increased the tumor growth more than the control cells.
These results confirming that huMETCAM/MUC18 plays an important role in increasing 
tumorigenesis and initiating metastasis of LNCaP cells, consistent with our earlier findings 
that huMETCAM/MUC18 is frequently expressed in the pre-malignant high-grade PIN and 
in human prostate cancer tissues [72]. Taken together, the hypothesis that METCAM/MUC18 
plays an important role in initiating prostate cancer progression is well-supported by evidence.
Recently, we further shown that huMETCAM/MUC18 also played a positive role in the pro-
gression of another prostate cancer cell line, DU145, by showing that the tumorigenesis of 
DU145 in an athymic nude mouse model was decreased when the endogenously expressed 
METCAM/MUC18 was decreased by knock-down with SiRNAs [54, 55].
3.6. METCAM/MUC18 plays a dual role in other tumors
In addition to melanoma, prostate cancer, breast cancer, ovarian cancer, and NPC, METCAM/
MUC18 is also expressed in other cancers, such as gestational trophoblastic tumors, leiomyo-
sarcoma, angiosarcoma, Kaposi’s sarcoma, some lung squamous and small cell carcinomas, 
and some neuroblastoma; however, the role of METCAM/MUC18 in the development of most 
of these cancers has not been investigated [65, 66]. In our preliminary tests, we observed 
that moMETCAM/MUC18 was expressed at a higher level in one angiosarcoma clone, SVR, 
which was transfected with H-Ras, than in an immortalized normal endothelial cell line con-
trol, MS-1 [62]. The higher expression level of moMETCAM/MUC18 was correlated with the 
higher tumorigenicity of the SVR cell line [69, 90], suggesting that METCAM/MUC18 pro-
moted the development of angiosarcoma [62, 69, 90]. Recent findings from other groups also 
suggest that METCAM/MUC18 also plays a positive role in the progression of osteosarcoma 
[91], hepatocellular carcinoma [92, 93], gastric cancer [94], non-small cell lung adenocarci-
noma [95], small cell lung cancer [96], and pancreatic cancer [98].
On the other hand, the possible tumor and metastasis suppressor role of METCAM/MUC18 
has also been extended from melanoma, ovarian cancer, and NPC, to colorectal cancer 
[97], pancreatic cancer [99], and perhaps, hemangioma [100]. Table 1 summarizes the role 
of METCAM/MUC18 in the tumor formation and/or cancer metastasis of various tumors/
cancers.
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Taken together, the dual role of METCAM/MUC18 may be explained by that the intrinsic 
properties of each cancer cell line may provide co-factors that either positively or negatively 
regulate METCAM/MUC18-mediated tumorigenesis and metastasis. To understand further 
the role of METCAM/MUC18 in these processes, it is essential to identify these intrinsic co-
factors in the future studies.
Tumor/cancers Tumorigenesis Metastasis References
Clinical prostate cancer and human 
prostate cancer cell lines
Increasing Increasing and affecting initiation 
in the early stage (PIN)
[51, 53–55, 70, 72]
Prostate adenocarcinoma in 
TRAMP mice
Increasing Increasing and affecting initiation 
in the early stage
[52]
Clinical melanoma and human 
melanoma cell lines
No effect Increasing and affecting at the 
late stage
[12, 67]
Mouse melanoma cells (K1735-3 
and 10)
No effect or suppression Increasing and affecting at the 
late stage
[13, 49, 71]
Mouse melanoma cells (K1735-9) Suppression Suppression [13, 50, 71]
Angiosarcoma Increasing Possible promotion, by not 
determined
[62, 69, 90]
Human breast cancer cell line 
MCF-7
Promotion Not determined [56]
Human breast cancer cell line 
SK-BR-3
Promotion Not determined [57–58]
Human breast cancer cell lines 
MDA-MB-231 and 468
Promotion Promotion [57, 77]
Hemangioma Possible suppression, but 
bot determined
Not determined [100]
Nasopharyngeal carcinoma type I Suppression Possible suppression, but not 
determined
[82, 83]
Nasopharyngeal carcinoma type II Promotion Possible augmentation, but not 
determined
[82, 84]
Ovarian cancer Suppression Suppression [48, 59, 60]
Colorectal cancer Suppression Suppression [97]
Gastric cancer Promotion Not determined [94]
Non-small cell lung carcinoma Promotion Not determined [95]
Small cell lung carcinoma Promotion Not determined [96]
Hepatocellular carcinoma Promotion Promotion [92, 93]
Osteosarcoma Promotion Not determined [91]
Pancreatic cancer Promotion or suppression Not determined [98, 99]
Table 1. The possible role of METCAM/MUC18 in tumor formation and/or cancer metastasis of various tumors/cancers.
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4. Possible molecular mechanisms of the huMETCAM/MUC18-
mediated progression of cancer
Since the discovery of huMETCAM/MUC18 in the 1980s, about three groups have worked on 
the role of huMETCAM/MUC18 in melanoma metastasis [12, 63, 64, 67], another group on the 
role of huMETCAM/MUC18 in the biology of endothelial cells [68], and our group joined in 
the effort to study the role of huMETCAM/MUC18 in the progression of melanoma and pros-
tate cancer, and later breast cancer, ovarian cancer, and NPC, as described above. Though we 
are beginning to understand the biology of METCAM/MUC18-mediated cancer progression, 
however, many questions of linking the regulation of the expression of this gene to its role in 
cancer progression are remained to be answered. For examples, the contribution of the pro-
tein structure and the glycosylation of the protein to the function of huMETCAM/MUC18 in 
the progression of cancer have not been systematically studied. How the protein mediates the 
interaction of tumor cells with the tumor microenvironment is not well studied. Though only 
limited information is available for huMETCAM/MUC18’s outside-in and inside-out signal-
ing in endothelial cells, and the signaling information for the METCAM/MUC18-mediated 
progression of various cancer cells are not much known. How the expression of METCAM/
MUC18 is regulated at the level of transcription is minimally studied. We will try to address 
these questions by taking advantage of the currently known information from various sources 
to propose possibilities for much needed studies in the future.
4.1. The presentation of huMETCAM/MUC18 on the surface of cancer tissues may 
be different from cancer to cancer
Our unique contribution to the biology of METCAM/MUC18 was mainly attributed to the 
high specificity of our chicken antibodies [70, 71], to reconcile the different, sometimes contro-
versial, findings [73, 86], we suggest that the presentation of huMETCAM/MUC18 on the cel-
lular surface in normal and carcinoma tissues may be different from cancer to cancer [70, 72]. 
HuMETCAM/MUC18 may be presented differently in various cancer cell lines because of 
different carbohydrate composition, differential distribution of huMETCAM/MUC18 in the 
cholesterol-enriched lipid raft membrane fraction of the plasma membrane, different interac-
tions of huMETCAM/MUC18 with other membrane proteins, and different lipid modifica-
tion of the protein. There appears to have some correlation of the predominant cytoplasmic 
expression of huMETCAM/MUC18 antigens with the malignant progression of human pros-
tate carcinomas, but not in human melanoma. To test the above possibilities, it is necessary to 
express the whole or a fragment of the protein in a large scale in human cancer cells lines in 
order to purify the protein for biochemical characterization and for crystallization and physi-
cal structure studies. Alternatively, to probe the functions of different parts of the molecule 
and for translational research, a complete set of monoclonal antibodies can be induced from 
the purified whole protein or its fragments. In line with these, a repertoire of mouse monoclo-
nal antibodies has been successfully constructed by Yen’s group [101]. We also intend to make 
a repertoire of rabbit monoclonal antibodies for the above purpose.
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4.2. Which domains of huMETCAM/MUC18 are required for tumorigenesis and 
metastasis?
The relation of the protein structure of huMETCAM/MUC18 to its functions in tumorigenesis 
and metastasis has not been systematically defined. For this purpose, the partial known infor-
mation of the functional domain(s) of the two huMETCAM/MUC18-related cell adhesion mol-
ecules in the Ig-like gene superfamily, such as CEA-CAM [31, 32] and ALCAM [102–104], might 
be used as a guide for designing tests to probe the functional domains in the external domain of 
huMETCAM/MUC18. The known functions of the cytoplasmic tail of several cell adhesion mol-
ecules may also provide clues to understand the function of the cytoplasmic tail of huMETCAM/
MUC18 in crosstalk with signal pathways leading to tumorigenesis and metastasis [105–107]. 
For example, the domain of CEACAM1 required for tumorigenesis seems to reside in the intra-
cellular cytoplasmic tail, but not in the extracellular domain [31, 32]. The N-terminal most Ig-like 
domain of the extracellular portion of ALCAM seems to be responsible for homophilic and het-
erophilic interactions [103, 104]. However, the domain(s) of these two molecules required for 
metastasis have not yet been studied. Since the information from these related proteins is very 
limited, we cannot logically predict the role of both the extracellular domain and the intracellu-
lar tail of the Ig-like CAMs in tumorigenesis and metastasis. To begin addressing this question, 
in the past, we have generated mutants deleted different domains of huMETCAM/MUC18 by 
using a special PCR method [108] and used them to determine their contribution to tumorigen-
esis. The ecto-domain of huMETCAM/MUC18 was similar to the whole wild type cDNA to be 
able to induce tumorigenesis of LNCaP cells in nude mice, suggesting that the ecto-domain 
alone was sufficient to induce tumor of human prostate cancer cells in vivo, implying that the 
cytoplasmic domain was not essential for this process [data not shown].
However, similar tests of using only the cytoplasmic domain have not been performed for 
LNCaP cells. Rather, the function of the cytoplasmic domain of huMETCAM/MUC18 was 
tested for the human ovarian cancer cell line BG-1 that the cytoplasmic domain alone was able 
to induce tumors in nude mice [data not shown].
In conclusion, we are not clear if this is true only for BG-1 cells or this is generally true for all 
cancer cell lines, which requires further studies.
4.3. The possible role of glycosylation in the huMETCAM/MUC18-mediated cancer 
metastasis
Glycosylation of a protein has been shown to affect the proper folding, stability, and/or activ-
ity of a protein [109]. Furthermore, the glycosylation of a cell adhesion molecule may affect its 
ability to induce metastasis of cancer cells [110–113].
Both huMETCAM/MUC18 and moMETCAM/MUC18 have an apparent molecular weight of 
about 150 kDa [114], because they are heavily glycosylated, sialylated, and post-translationally 
modified. We have shown that the apparent molecular weight of huMETCAM/MUC18 
expressed in different human cancer cell lines was decreased after digestion with N-glycosidase 
F and neuraminidase (sialidase), but not with O-glycosidase or endoglycosidase H [62, 69], 
suggesting that huMETCAM/MUC18 has both sialic acid and N-glycans as carbohydrate 
side chains. Glycosylation in different cancer may be different that has been shown by using 
the anti-HNK-1 monoclonal antibody Leu 7 to probe the expression of HNK-1 epitope, 
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a sulfated-glycan with the structure of sulfo → 3GlcAβ1 → 3Galβ1 → 4GlcNA-cβ1→ R, in 
melanomas and prostate cancer tissues [115–120]. The expression level of the HNK-1 epitope is 
proportional to that of human METCAM/MUC18 in human melanoma, and both are predomi-
nantly expressed on the plasma membrane of melanoma cells. In contrast, the HNK-1 epitope 
is found to be predominantly present in the cytoplasm of human prostate epithelial cells. In 
addition, different from the increased expression level of huMETCAM/MUC18 in prostate can-
cer, the expression of the HNK-1 epitope is decreased in the more advanced grades of human 
prostate cancer [120]. We suggest that the sugar moieties in the N-glycans of huMETCAM/
MUC18 in human prostate cancer cells are different from that in melanoma cells; this may be 
related to its more profound effect on promoting the tumorigenesis and metastasis of human 
prostate cancer LNCaP cells than that of melanoma cells [12, 51, 69, 70]. Thus, we hypothesize 
that the N-glycans at the N-glycosylation sites of huMETCAM/MUC18 should have a sig-
nificant effect on their in vitro motility and invasiveness and other in vitro cellular behaviors 
(for example, cell-cell adhesion and cell-extracellular matrix interaction) as well as tumori-
genesis and metastasis of human prostate cancer and melanoma cells and very likely also in 
other human cancer cells that express METCAM/MUC18, since glycosylation of huMETCAM/
MUC18 may affect its ability to mediate cell-cell adhesion and cell-extracellular matrix interac-
tion. This notion is supported by a recent publication that GCNT3 is an upstream regulator of 
METCAM and it glycosylates METCAM/MUC18 and extends its half-life, leading to further 
elevation of S100A8/A9-mediated cellular motility in melanoma cells [121].
The human huMETCAM/MUC18 protein has nine potential N-glycosylation sites (Asn-X-Ser/Thr 
or N-X-S/T sites) [63, 64, 70] and the mouse METCAM/MUC18 has seven [71]. Their locations on 
huMETCAM/MUC18 are depicted in Figure 1. Six N-glycosylation sites are conserved between 
the two proteins: 56/58 NL/FS, 418/420NRT, 449/451NLS, 467NGT/469NGS, 507NTS/509NTT, 
and 544/546NST [69]. Since the apparent molecular weight of huMETCAM/MUC18 and moMET-
CAM/MUC18 in the SDS gel are similar, we suggest that only these six conserved N-glycosylation 
sites are actually glycosylated. All these N-glycosylation sites are located in the external domains 
of V1, C′, C″, and X. The effect of N-glycosylation on the function of huMETCAM/MUC18 can be 
tested by using genetic means to alter the N-glycosylation sites. First, we should test the effect of 
mutations in the six conserved sites of the huMETCAM/MUC18 on in vitro cell-cell aggregation 
and cell-extracellular matrix adhesion and on in vivo tumorigenesis and metastasis of human can-
cer cells. The N-glycosylation site can be point mutated from Asn to Ala or Gln [122, 123] or may 
be linker-scanning mutated by replacing the three codons (the nine nucleotide sequence) with a 
nine bp oligonucleotide containing a unique restriction site sequence [124]. Both kinds of muta-
tion are better than deletion mutations, since they do not change the relative physical location of 
the mutated sequences and thus the phenotype of the mutant is directly related to the substituted 
sequence without the complicated influence of the added sequences from the surrounding region 
of interest. The linker-scanning mutations from our experience are superior to the point muta-
tions because they usually manifest a more dramatic phenotype [124].
4.4. The heterophilic ligands of METCAM/MUC18 may play an important role in 
the cell-cell and cell-extracellular matrix interactions and cancer metastasis
To further understand how huMETCAM/MUC18 mediates metastasis of cancer cells to certain 
target organs, it is important to identify the heterophilic ligand(s) of huMETCAM/MUC18 and 
to know how it regulates cellular behaviors, and how it interacts with members of the signal 
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transduction pathways. Previous studies suggest that huMETCAM/MUC18 prefers to interact 
with heterophilic ligand(s) [125, 126], which, however, has not been identified. But at least we 
know that some components of proteoglycans such as, glycosaminoglycan, hyaluronic acid, 
dermatan sulfate, keratan sulfate, heparin, heparan sulfate, chondroitin-6-sulfate, and heparan 
sulfate proteoglycan, have been excluded [125, 126]. The heterophilic ligands of huMETCAM/
MUC18 are highly likely to be proteins. The proteins possessing SH3 domain [127] may be the 
possible candidates; however, the proteins containing the SH3 domain may not be the real ligands 
since they interact with MUC18 with a low affinity. The neurite outgrowth factor (a member of 
the laminin family) [128] may be another possible candidate; however, the cDNA gene of the neu-
rite outgrowth factor has not been cloned for further characterization. To identify the authentic 
heterophilic ligands of huMETCAM/MUC18, stringent biochemical criteria should be employed.
To search for the ligand(s), many methods may be employed, such as immunoaffinity pull-
down method [129], METCAM/MUC18-GST fusion protein pull-down method [69], METCAM/
MUC18-AP fusion method to screen an expression library [130, 131], or METCAM/MUC18 used 
for screening counter-acting peptides in a phage library expressing random peptides [132, 133]. 
So far, we have attempted to use an immunoaffinity pull-down method to identify the hetero-
philic ligands of huMETCAM/MUC18. From our preliminary results, we found that a protein 
of 72 kDa may be a potential ligand, which is expressed on the cellular surface of two human 
prostate cancer cell lines and one human melanoma cell line [69]. This putative ligand protein 
appeared to be present in the extract of the human prostate cancer cell line, PC-3, more than 
that in DU145. We excluded the possibility that this protein may be the breakdown product of 
huMETCAM/MUC18 because of its discrete size. We are in the process of preparing a sufficient 
quantity of the protein for further characterization with mass spectrometry. In addition, we 
have successfully expressed a huMETCAM/MUC18-ectodoamin-GST fusion protein in LNCaP 
cells. The fusion protein will be purified and also used for pulling down ligands. Alternatively, 
we have used a huMETCAM/MUC18-AP fusion protein to screen a human brain cDNA expres-
sion library; preliminary trials indicated that this methodology appears to be promising.
4.5. METCAM/MUC18-mediated signal transduction and cancer metastasis
The intracellular cytoplasmic tail of huMETCAM/MUC18 contains three consensus sequences 
to be recognized by PKC, one by PKA, and one by CK2 [63, 69, 70]. Though not biochemically 
proven, the cytoplasmic tail presumably is phosphorylated by these kinases. It probably has 
a capacity to crosstalk and network different signal pathways, similar to the cytoplasmic tails 
of other CAMs [106, 107, 134, 135]. Thus METCAM/MUC18, as an integral membrane protein 
and a cell adhesion molecule, should mediate inside-out and outside-in signals, which may 
be participating in cell-cell communication, cell-extracellular matrix interaction, and affecting 
the cellular motility and invasiveness [134, 135]. Furthermore, its interaction with cognate 
heterophilic ligand(s) may affect how it promotes angiogenesis and how it mediates targeting 
to specific organs and facilitates metastasis. Moreover, it may interact with androgen/andro-
gen receptor, growth factors/receptors, chemokines/receptors, and Ca2+-mediated signaling 
members. Figure 2 summarizes the possible crosstalk of huMETCAM/MUC18 with many 
members of signal transduction pathways, which are supported by the following:
The downstream signal transduction of this protein has been studied in endothelial cells. 
Anfosso et al. [68] showed that antibody cross-linked huMETCAM/MUC18 (which mimics cell 
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adhesion on the cell surface) induces phosphorylation of both FAK and PyK2 (a member of the 
FAK family) and association of FAK with paxillin in the endothelial cells, which leads to the acti-
vation of focal adhesion complexes, similar to the outside-in signaling triggered by the engage-
ment of integrins with the extracellular matrix. In addition, the engagement of huMETCAM/
MUC18 also triggers direct association with Fyn, a member of the c-Src family, which activates 
adhesion-associated signaling cascades and cytoskeleton rearrangement, leading to increasing 
motility, and invasiveness. Since FAK and PyK2 do not directly associate with huMETCAM/
MUC18 and the molecules that link the huMETCAM/MUC18 with FAK or PYK2 have not been 
identified, but huMETCAM/MUC18, similar to integrins, may use Fyn (and talin) for this pur-
pose. We suggest that it is likely that focal adhesion complexes and signaling cascades may also 
be present in the prostate cancer and melanoma cells, since the over-expression of huMETCAM/
MUC18 increases motility and invasiveness of human prostate cancer cells and melanoma cells.
Anfosso et al. further found that huMETCAM/MUC18 engagement also induces a Ca2+ influx, 
indicating that it is also able to initiate a store-operated calcium mobilization [136]. Ca2+ inside 
the cell may play a very important role—more so than other secondary messengers—in focal 
adhesion-induced actin cytoskeleton rearrangement and cellular motility, which is supported 
by the fact that locally elevated Ca2+ inside the cell triggers focal adhesion disassembly and 
enhances residency of focal adhesion kinase at focal adhesions [137, 138]. The link between 
the cell adhesion role of huMETCAM/MUC18 with Ca2+ influx is supported by the evidence 
that human METCAM/MUC18 is coupled to a Fyn-dependent pathway that triggers activa-
tion of phospholipase C-γ1 via tyrosine phosphorylation, which leads to increased Ca2+ influx 
that is in turn required for the tyrosine phosphorylation of PyK2 and p130Cas and formation 
of a complex between PyK2, p130Cas, and paxillin, which in turn leads to cell adhesion and 
cell motility. Taken together, huMETCAM/MUC18 is a signaling molecule involved in the 
dynamics of actin cytoskeleton rearrangement. The elevation of Ca2+ influx also has other 
effects: it is linked to Ras-Raf1-MAP kinase via PyK2 and involved in cell proliferation by 
activating phospholipase C-γ1, which in turn activates PKCs that affects cell proliferation, 
differentiation, and transcriptional control of other genes (for example, c-Myc target genes); 
and it may directly activate transcription factors, such as NF-kB, NF-AT, and CREB, which 
regulate transcription of genes in proliferation, survival, and/or apoptosis [139].
AKT (or PKB), the cellular homolog of the retroviral oncogene v-AKT, is a serine/threonine 
kinase. AKT is a key member in the AKT/PI3K/PTEN signaling pathway [140]. AKT is acti-
vated by phosphorylation at Thr 308 and Ser473 by its upstream factor, PI3 kinase, and is 
inactivated by de-phosphorylation by PTEN, a tumor suppressor. Upon activation, AKT pro-
motes cell survival by interfering with the cell apoptosis (when cells are exposed to pro-apop-
totic signals, such as growth factor withdraw, irradiation, DNA damage, detachment, and the 
administration of apoptosis-inducing reagents) [140] and also promotes motility, prolifera-
tion, growth, angiogenesis, and the activation of mTOR (mammalian target of rapamycin) 
[141]. AKT also can be activated by Ras, which in turn is activated by a growth factor receptor 
or by RTK and survival factors, IGF1. In melanoma cells, when AKT activation is inhibited, 
huMETCAM/MUC18 expression is reduced. When AKT is super-activated, huMETCAM/
MUC18 expression is increased. On the other hand, the over-expression of huMETCAM/
MUC18 in melanoma cells led to further activation of AKT, resulting in cell survival under 
stress conditions [142]. It is not clear how the expression of AKT is directly or indirectly affect-
ing the expression of huMETCAM/MUC18 and which isoforms is involved, since there are 
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three isoforms of AKT: AKT-1, AKT-2, and AKT-3. One possible crosstalk between METCAM/
MUC18 and AKT may be linked by casein kinase 2, as described further.
Casein kinase 2 (CK2) was discovered in the 1950s. The history of CK2 is full of paradoxes 
and unexpected findings [143]. The α-subunits and the β-subunits of CK2 are found to be 
un-coordinately distributed in different cellular compartments, suggesting that the interac-
tion partners of the α-subunits and the β-subunits may be different and much more complex 
than we have previously thought. CK2 is constitutively active, and no oncogenic CK2 mutant 
is known; but high CK2 activity correlates to neoplasia. It was thought to be one of the most 
pleiotropic protein kinases. However, a phospho-proteomics analysis of these CK2 null cells 
suggests that CK2 pleiotropy may be less pronounced than expected, supporting the idea that 
the phospho-proteome generated by this kinase is flexible and not rigidly pre-determined. 
Furthermore, CK2 is dispensable, since it can be replaced by other kinases to perform the 
phosphorylation of critical sites whenever CK2 activity is nullified. CK2 may also be involved 
in cell survival by directly affecting AKT activity or indirectly interacting with members of 
the AKT survival pathway. We suggest that a potential sequence present in the huMETCAM/
MUC18 cytoplasmic tail may be recognized by CK2 as its substrate and may link the recipro-
cal mutual effect between huMETCAM/MUC18 and AKT.
PKC is the most extensively studied among all protein kinases. A huge number of mem-
bers are involved in the family of PKC. PKCs are encoded by nine different genes. It has a 
large family including three major families of isozymes with distinct regulation: cPKC (PKCα, 
PKCβΙ, PKCβII, and PKCγ), nPKC (PKCδ, PKCε, PKCη, and PKCθ), and aPKC (PKCλ, 
PKCζ, and PKCι) [144]. In addition, there are the PKC-related kinases, PRK ½ [145] and PKC-
binding partners [146]. The classical PKCs (cPKCs) are activated by PS, calcium, and DAG 
or PMA; the novel PKCs (nPKCs) are activated by PS and DAG or PMA; the atypical PKCs 
(aPKCs) are independent of PS, calcium, and DAG. PKC isozymes are key regulators of cel-
lular function, such as growth, differentiation, cell survival, neurotransmission, carcinogen-
esis, and cancer progression [144]. PKCs control multiple functions associated with cancer 
progression, in many cases in opposite manners. Depending on the context, PKCs can act 
either as promoters or suppressors of the cancer phenotype [147]. The PKC-related kinases, 
PRK ½ and PKC-binding partners may regulate and expand the functions of PKCs by posi-
tioning individual PKCs in the appropriate location to respond to specific receptor-mediated 
activating signals, bringing them in close contact with substrate proteins, directing them in 
vesicle trafficking between compartments, or integrating PKC-mediated signaling with other 
signaling pathways [145, 146]. Increased regulation of PKCα has been associated with the 
malignant progression of melanoma and that of PKCβII with the progression of colon/rectal 
cancer [144]. Up-regulation of PKCα, PKCε, and PKCζ, and down-regulation of PKCβ was 
associated with the progression of prostate cancer [144]. Over-expression of PKCε was suf-
ficient to transform androgen-sensitive LNCaP cells into an androgen-independent variant 
[144]. The contribution of PKCs to METCAM/MUC18-mediated tumor growth and metastasis 
has not been studied. At least, it is highly possible that PKCs may phosphorylate the cytoplas-
mic tail of METCAM/MUC18 at the three potential PKC phosphorylation sites; however, it is 
not clear which isoform of PKC is responsible it. Furthermore, some inside-out signals may 
turn on some of the PKC members, which in turn may interact with the cytoplasmic tail of 
huMETCAM/MUC18, leading to tumor cell survival, tumor vascularization, cytoskeleton re-
organization, focal adhesion, migration, and invasiveness [147].
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PKA is involved in cAMP-mediated signal transduction. The huMETCAM/MUC18 pro-
moter may be regulated by PKA [148], since it contains a consensus CREB-binding site, 
as shown in Figure 3. Thus, the expression of huMETCAM/MUC18 may be regulated by 
PKA. Furthermore, the activity/function of huMETCAM/MUC18 may be regulated by PKA-
mediated signals, perhaps after the phosphorylation of the cytoplasmic tail. Since PKA has 
been shown to regulate the Ca2+ channels and pumps, the Ca2+ influx induced by the huMET-
CAM/MUC18 engagement may also be regulated by PKA [139]. The effect of PKA on in vitro 
tumor growth and in vitro motility and invasiveness may be investigated after augmentation 
of the PKA activity by treatment of cells with forskolin. The effect of PKA on these processes 
may be reversed by treatment with specific inhibitors to reduce the PKA activity.
4.6. Transcriptional regulation of huMETCAM/MUC18 gene
Only a few studies have been done to understand the mechanism of transcriptional control 
of METCAM/MUC18 gene. The sequence of 900 bp in the core promoter region of huMET-
CAM/MUC18 has been characterized [64]. This promoter does not have a TATA box, but is 
GC-rich, which contains putative binding sites for SP-1, CREB [148], AP-2 [149, 150], c-Myb 
[151], N-Oct2 (Brn2) [152], Ets [153], CArG [154], and Egr-1 [155] and three insulin responsive 
elements (one Ets and two E-box motifs) [156], suggesting that huMETCAM/MUC18 expres-
sion may be regulated by growth-related signals [62, 69] (Figure 3).
AP-2 is a transcription repressor for the huMETCAM/MUC18 gene and it is also a suppres-
sor for the huMETCAM/MUC18-mediated metastasis [149, 150]. This is supported by the evi-
dence that transfection of highly metastatic melanoma cells (AP-2−/MUC18+) with the AP-2 
gene resulted in a down-regulation of huMETCAM/MUC18 gene and inhibited their tumor 
growth and metastasis in nude mice [149]. Similar down-regulation of huMETCAM/MUC18 
probably occurs in human prostate cancer cells [150]. Since the loss of AP-2 expression is at the 
early stage of prostate cancer development, this is consistent with our notion that MEMCAM/
MUC18 plays an important role in initiating the development of prostate cancer. The loss of 
AP-2 expression at the late stage of melanoma is also consistent with our hypothesis that MEM/
MUC18 plays a key role only in the late stage of the development of melanoma. ZBTB7A has 
Figure 3. Putative transcription factor-recognized motifs in the 900 bp core promoter and 5–10 kbp upstream region of 
the huMETCAM/MUC18 gene.
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been shown to repress transcription of METCAM/MUC18 gene in melanoma [157]. METCAM/
MUC18 gene in osteosarcoma has been partly controlled by the transcription factor YY1 [158].
In addition to the sequence in the core promoter region, some upstream sequences should 
be required for the tissue-specific regulation of huMETCAM/MUC18 gene, since this 900 bp 
promoter region did not contain the necessary sequences to confer tissue specificity of the 
huMETCAM/MUC18 expression [159]. A recent finding appears to support this notion that 
Ets sequence in the 10 kbp upstream region is involved in the regulation of the expression of 
huMETCAM.MUC18 gene [160]. The sequence of the upstream region of the huMETCAM/
MUC18 promoter may be obtained by searching in the Celera or other web sites. We have 
obtained several clones that contain at least 4 kbp of the gene for future studies.
Furthermore, epigenetic control of the huMETCAM/MUC18 gene has not been extensively 
studied. Nevertheless, the epigenetic control of the expression of huMETCAM/MUC18 gene 
has been demonstrated in NPC [161] and prostate cancer [162]. HuMETCAM/MUC18 gene is 
located on human chromosome 11q23.3 [127] which has been shown to be methylated in NPC, 
suggesting that the expression of this gene may be regulated by epigenetic controls. METCAM/
MUC18 has been shown to be methylated in most of the early stage of prostate cancer [162].
5. Conclusions and clinical applications
METCAM/MUC18 may play a key positive function in the progression of prostate cancer, 
melanoma, breast cancer, gastric cancer, hepatocellular carcinoma, lung cancer, pancreatic 
cancer, and NPC type II. On the other hand, it may also have a key function in suppressing the 
progression of one mouse melanoma cell line, ovarian cancer, NPC type I, colorectal cancer, 
hemangioma, and perhaps other cancers. To further understand its role in these processes, it 
is essential to further define its functional domains, identify its cognate ligands and regula-
tors, and study its crosstalk with members of various signal transduction pathways and the 
regulation of its expression at the level of transcription. The knowledge obtained from our 
studies should be useful for designing effective means to arrest, or even better, to block the 
metastatic potential of these cancers. For example, a preclinical trial of using doxazosin, a 
α1-adrenergic antagonist, which has been used to treat the BPH patients, has been shown to 
reduce prostate cancer metastasis in the TRAMP mouse model [163]. Furthermore, the suc-
cess of preclinical trials has been demonstrated in using a fully humanized anti-METCAM/
MUC18 antibody against melanoma growth and metastasis [164] and in using a mouse anti-
METCAM/MUC18 monoclonal antibody against angiogenesis and tumor growth (hepatocel-
lular carcinoma, leiomyosarcoma, and pancreatic cancer) [165]. However, the dual role of 
METCAM/MUC18 in cancer progression warns us an important point in clinical applications 
that we should not be hasty in using monoclonal antibodies or siRNA for clinical trials, rather 
we should spend more effort on tailoring a personalized treatment in the future.
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